Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 2/20 | 0.43 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.38 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NPY4R | P50391 | 3/20 | 0.35 |
| ▸ | NPY1R | P25929 | 2/20 | 0.35 |
| ▸ | NPY2R | P49146 | 2/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL29129604 | 1.00 | CTSC (0.43) | CTSCALPIPKMPTGS1XIAP | |
| Arginine SCHEMBL285989 | 1.00 | CTSC (0.43) | CTSCALPIPKMPTGS1XIAP | |
| Arginine SCHEMBL28444628 | 0.98 | CTSC (0.42) | CTSCALPIPKMPTGS1XIAP | |
| Arginine SCHEMBL27385572 | 0.98 | CTSC (0.42) | CTSCALPIPKMPTGS1XIAP | |
| Arginine SCHEMBL11905110 | 0.97 | ALPI (0.41) | CTSCALPIPKMPTGS1XIAP | |
| Arginine SCHEMBL27686839 | 0.96 | CTSC (0.41) | CTSCALPIPKMPTGS1XIAP | |
| Arginine SCHEMBL5071059 | 0.96 | CTSC (0.41) | CTSCALPIPKMPTGS1XIAP | |
| Arginine SCHEMBL3656565 | 0.96 | CTSC (0.41) | CTSCALPIPKMPTGS1XIAP | |
| Arginine SCHEMBL10428541 | 0.95 | CTSC (0.40) | CTSCALPIPKMPTGS1XIAP | |
| Arginine SCHEMBL4284805 | 0.95 | CTSC (0.40) | CTSCALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120027706-A1 | METHODS FOR TREATING SKIN PIGMENTATION | SHAPIRO STANLEY S (US) | 2012-02-02 | — | — | US | claimed |
| JP-4401441-B2 | — | — | 2010-01-20 | — | — | JP | claimed |
| US-20080249029-A1 | Administering (S)-N-Methyl-D-phenylalanyl-N-[4-[(aminoiminomethyl)aminol-1-(2-benzothiazolylcarbonyl)butyl-L-prolinamide as a protease activated receptor-2 modulator | SHAPIRO STANLEY S | 2008-10-09 | — | — | US | claimed |
| JP-2001502360-A | — | — | 2001-02-20 | — | — | JP | claimed |
| CN-1234735-A | Method for treating skin pigmentation | JOHNSON & JOHNSON CONSUMER (US) | 1999-11-10 | — | — | CN | claimed |
| EP-0948308-A1 | METHODS FOR TREATING SKIN PIGMENTATION | JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. (US) | 1999-10-13 | — | — | EP | claimed |
| WO-1999004752-A9 | METHODS FOR TREATING SKIN PIGMENTATION | JOHNSON & JOHNSON CONSUMER (US) | 1999-04-08 | — | — | WO | claimed |
| WO-1999004752-A2 | METHODS FOR TREATING SKIN PIGMENTATION | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 1999-02-04 | — | — | WO | claimed |
| US-20120027706-A1 | METHODS FOR TREATING SKIN PIGMENTATION | SHAPIRO STANLEY S (US) | 2012-02-02 | — | — | US | disclosed |
| US-8039026-B1 | Methods for treating skin pigmentation | JOHNSON & JOHNSON CONSUMER COMPANIES, INC (US) | 2011-10-18 | — | — | US | disclosed |
| US-20080249029-A1 | Administering (S)-N-Methyl-D-phenylalanyl-N-[4-[(aminoiminomethyl)aminol-1-(2-benzothiazolylcarbonyl)butyl-L-prolinamide as a protease activated receptor-2 modulator | SHAPIRO STANLEY S | 2008-10-09 | — | — | US | disclosed |
| EP-1037653-B1 | COMPOSITIONS AND METHODS FOR REGULATING PHAGOCYTOSIS AND ICAM-1 EXPRESSION | JOHNSON & JOHNSON CONSUMER (US) | 2006-09-06 | — | — | EP | disclosed |
| CN-1188164-C | Compositions and methods for regulating phagocytosis and ICAM-1 expression | JOHNSON & JOHNSON CONSUMER (US) | 2005-02-09 | — | — | CN | disclosed |
| CN-1163261-C | Method of treating skin pigmentation | ���Ǿ� | 2004-08-25 | — | — | CN | disclosed |
| US-20020065300-A1 | METHODS FOR TREATING SKIN PIGMENTATION | JOHNSON & JOHNSON CONSUMER INC. | 2002-05-30 | — | — | US | disclosed |
| US-6323219-B1 | PRODRUGS AND PEPTIDES FOR ANTIINFLAMMATORY AGENTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-11-27 | — | — | US | disclosed |
| EP-1077063-A2 | Methods for treating skin pigmentation | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2001-02-21 | — | — | EP | disclosed |
| CN-1283507-A | Method of treating skin pigmentation | JOHNSON & JOHNSON CONSUMER (US) | 2001-02-14 | — | — | CN | disclosed |
| CN-1282254-A | Compositions and methods for modulating phagocytosis and ICAM-1 expression | JOHNSON & JOHNSON CONSUMER (US) | 2001-01-31 | — | — | CN | disclosed |
| CN-1234735-A | Method for treating skin pigmentation | JOHNSON & JOHNSON CONSUMER (US) | 1999-11-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027706-A1 | METHODS FOR TREATING SKIN PIGMENTATION | TYR, MC1R, NQO1 | CTSC 421/4885ALPI 3246/4885PKM 1002/4885 |
| US-20080249029-A1 | Administering (S)-N-Methyl-D-phenylalanyl-N-[4-[(aminoiminomethyl)aminol-1-(2-benzothiazolylcarbonyl)butyl-L-prolinamide as a protease activated receptor-2 modulator | MC1R, F2RL1, F2R | CTSC 58/4885ALPI 4092/4885PKM 1831/4885 |
| US-20020065300-A1 | METHODS FOR TREATING SKIN PIGMENTATION | TYR, MC1R, NQO1 | CTSC 421/4885ALPI 3246/4885PKM 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.